Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNG | P07510 | 1/20 | 0.33 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14856128 | 1.00 | MAPT (0.36) | MAPTSMN1; SMN2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL14915004 | 1.00 | MAPT (0.36) | MAPTSMN1; SMN2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL14915002 | 1.00 | MAPT (0.36) | MAPTSMN1; SMN2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL2935813 | 0.97 | — | — | |
| SCHEMBL2935816 | 0.97 | — | — | |
| SCHEMBL6183540 | 0.97 | — | — | |
| SCHEMBL14915022 | 0.92 | — | — | |
| SCHEMBL14856116 | 0.92 | — | — | |
| SCHEMBL31484180 | 0.92 | — | — | |
| SCHEMBL14500222 | 0.90 | MAPT (0.36) | MAPTSMN1; SMN2TDP1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106883196-B | A kind of synthetic method of first piperazine raw medicine | 中棉小康生物科技有限公司 | 2019-03-22 | — | — | CN | claimed |
| CN-106883196-A | A kind of synthetic method of first piperazine active compound | 安阳市小康农药有限责任公司 | 2017-06-23 | — | — | CN | claimed |
| EP-0350990-B1 | Pyridazinone derivatives | AKZO NOBEL NV (NL) | 1995-09-20 | — | — | EP | claimed |
| US-4952571-A | Pyridazinone derivatives | AKZO, N.V. (NL) | 1990-08-28 | — | — | US | claimed |
| EP-0350990-A1 | Pyridazinone derivatives | Akzo Nobel N.V. (NL) | 1990-01-17 | — | — | EP | claimed |
| WO-2023159148-A2 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023066377-A1 | NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 索智生物科技（浙江）有限公司 | 2023-04-27 | — | — | WO | disclosed |
| CN-106883196-B | A kind of synthetic method of first piperazine raw medicine | 中棉小康生物科技有限公司 | 2019-03-22 | — | — | CN | disclosed |
| EP-3205648-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| EP-3205648-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | Seragon Pharmaceuticals, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| CN-106883196-A | A kind of synthetic method of first piperazine active compound | 安阳市小康农药有限责任公司 | 2017-06-23 | — | — | CN | disclosed |
| EP-2580210-B1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-20140107095-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | SERAGON PHARMACEUTICALS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20130345215-A1 | PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-12-26 | — | — | US | disclosed |
| US-20130116232-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1859793-A1 | NOVEL COMBINATIONAL USE OF SULFONAMIDE COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2007-11-28 | — | — | EP | disclosed |
| EP-0350990-B1 | Pyridazinone derivatives | AKZO NOBEL NV (NL) | 1995-09-20 | — | — | EP | disclosed |
| US-5219866-A | Antitumor agents | ASTA MEDICA AG (DE) | 1993-06-15 | — | — | US | disclosed |
| US-4952571-A | Pyridazinone derivatives | AKZO, N.V. (NL) | 1990-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047278-A1 | Novel Combinational Use of Sulfonamide Compound | EGFR, KIT, ERBB2 | MAPT 4340/4885SMN1; SMN2 2841/4885TDP1 4646/4885 |
| US-20130116232-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | MAPT 3693/4885SMN1; SMN2 4803/4885TDP1 4369/4885 |
| US-20130345215-A1 | PYRAZOLOPYRIMIDONE AND PYRAZOLOPYRIDONE INHIBITORS OF TANKYRASE | TNKS1BP1, TPI1, TNKS | MAPT 3693/4885SMN1; SMN2 3043/4885TDP1 22/4885 |
| US-20140107095-A1 | ESTROGEN RECEPTOR MODULATORS AND USES THEREOF | ESR2, ESRRG, GPER1 | MAPT 3601/4885SMN1; SMN2 4806/4885TDP1 4396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.